15:49:16 EDT Fri 12 Jul 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:NKTR - NEKTAR THERAPEUTICS - http://www.nektar.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NKTR - Q6.31.40·1.412.21.41+0.053.71,324.01,6742,5321.35  1.46  1.32011.928  0.412615:32:45Jun 1215 min RT 2¢

Recent Trades - Last 10 of 2532
Time ETExPriceChangeVolume
15:32:45Q1.410.05100
15:32:37Q1.40990.0499150
15:32:24Q1.410.05100
15:31:54Q1.410.05100
15:31:54Q1.410.05100
15:31:52Q1.410.05100
15:31:28Q1.410.05100
15:31:28Q1.410.05100
15:30:34Q1.4050.04533
15:30:34Q1.4050.04538

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-06-12 09:30U:NKTRNews ReleaseNektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
2024-05-30 18:00U:NKTRNews ReleaseNektar Management to Present at Upcoming Investor Conferences
2024-05-09 16:15U:NKTRNews ReleaseNektar Therapeutics Reports First Quarter 2024 Financial Results
2024-05-02 18:00U:NKTRNews ReleaseNektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
2024-03-22 14:00U:NKTRNews ReleaseNektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
2024-03-05 09:00U:NKTRNews ReleaseNektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
2024-03-04 16:15U:NKTRNews ReleaseNektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
2024-03-04 08:30U:NKTRNews ReleaseNektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
2024-02-27 18:00U:NKTRNews ReleaseNektar Management to Present at the TD Cowen 44th Annual Health Care Conference
2024-02-26 18:00U:NKTRNews ReleaseNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
2024-01-03 18:00U:NKTRNews ReleaseNektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
2023-12-11 18:00U:NKTRNews ReleaseNektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
2023-11-07 16:15U:NKTRNews ReleaseNektar Therapeutics Reports Third Quarter 2023 Financial Results
2023-10-31 18:00U:NKTRNews ReleaseNektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
2023-10-13 08:30U:NKTRNews ReleaseNektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
2023-10-02 09:00U:NKTRNews ReleaseNektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
2023-09-27 09:00U:NKTRNews ReleaseNektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
2023-09-13 09:00U:NKTRNews ReleaseNektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
2023-09-06 18:00U:NKTRNews ReleaseNektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
2023-08-08 16:15U:NKTRNews ReleaseNektar Therapeutics Reports Second Quarter 2023 Financial Results